Direct oral anticoagulants in adults with congenital heart disease – Role of chronic kidney disease
We thank Yildirim and colleagues for their interest in our study [1]. Direct oral anticoagulants (DOACs) are increasingly used in patients with chronic kidney disease (CKD). Recent guidelines even recommend apixaban as reasonable for patients with atrial fibrillation (AF) and end-stage CKD [2]. Yildirim et al. asked for details regarding our patients with CKD and bleeding events. This information was presented in Table 3 [1]. To summarize, two patients with renal disease had a bleeding event: one on apixaban (5 mg b.i.d.), and the other on rivaroxaban (10 mg/day).
Source: International Journal of Cardiology - Category: Cardiology Authors: Claudia Pujol, Mara M üssigmann, Peter Ewert, Oktay Tutarel Tags: Letter to the Editor Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Chronic Kidney Disease | Heart | Heart Disease | Study | Urology & Nephrology